ATE449762T1 - Kristalline formen einer biphenylverbindung - Google Patents

Kristalline formen einer biphenylverbindung

Info

Publication number
ATE449762T1
ATE449762T1 AT06737787T AT06737787T ATE449762T1 AT E449762 T1 ATE449762 T1 AT E449762T1 AT 06737787 T AT06737787 T AT 06737787T AT 06737787 T AT06737787 T AT 06737787T AT E449762 T1 ATE449762 T1 AT E449762T1
Authority
AT
Austria
Prior art keywords
crystalline forms
biphenyl compound
biphenyl
compound
crystalline
Prior art date
Application number
AT06737787T
Other languages
English (en)
Inventor
Sabine Axt
Timothy J Church
Viengkham Malathong
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36540140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE449762(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Inc filed Critical Theravance Inc
Application granted granted Critical
Publication of ATE449762T1 publication Critical patent/ATE449762T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06737787T 2005-03-10 2006-03-09 Kristalline formen einer biphenylverbindung ATE449762T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66020805P 2005-03-10 2005-03-10
PCT/US2006/008644 WO2006099165A1 (en) 2005-03-10 2006-03-09 Crystalline forms of a biphenyl compound

Publications (1)

Publication Number Publication Date
ATE449762T1 true ATE449762T1 (de) 2009-12-15

Family

ID=36540140

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06737787T ATE449762T1 (de) 2005-03-10 2006-03-09 Kristalline formen einer biphenylverbindung

Country Status (24)

Country Link
US (12) US20070112027A1 (de)
EP (1) EP1856050B1 (de)
JP (2) JP5009894B2 (de)
KR (1) KR101270183B1 (de)
CN (1) CN101163677B (de)
AR (2) AR053336A1 (de)
AT (1) ATE449762T1 (de)
AU (1) AU2006223325B2 (de)
CA (1) CA2599236C (de)
CY (1) CY1109775T1 (de)
DE (1) DE602006010668D1 (de)
DK (1) DK1856050T3 (de)
ES (1) ES2337604T3 (de)
HK (1) HK1114608A1 (de)
HR (1) HRP20100035T1 (de)
IL (1) IL185471A (de)
MX (1) MX2007011083A (de)
MY (1) MY147792A (de)
PE (1) PE20061347A1 (de)
PL (1) PL1856050T3 (de)
PT (1) PT1856050E (de)
SI (1) SI1856050T1 (de)
TW (1) TWI372749B (de)
WO (1) WO2006099165A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7416328B2 (en) * 2004-12-28 2008-08-26 Waters Investments Limited System and method for a thermogravimetric analyzer having improved dynamic weight baseline
TWI372749B (en) 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
US7973055B2 (en) 2006-03-09 2011-07-05 Theravance, Inc. Crystalline forms of a biphenyl compound
CA2709071C (en) 2007-12-14 2016-11-15 Labogroup S.A.S. Delivering aerosolizable food products
EP2103939A1 (de) * 2008-03-20 2009-09-23 sanofi-aventis Fluoreszenzbasiertes Assay zur Detektion von Modulationskomponenten des Natrium-/Kalziumaustauschers (NCX) im Umkehrmodus
EP2103944A1 (de) * 2008-03-20 2009-09-23 sanofi-aventis Fluoreszenz-basiertes Assay zum Erkennen von Substanzen, die den "forward mode" des Natrium/Calcium Austauschers modulieren
US8030957B2 (en) 2009-03-25 2011-10-04 Aehr Test Systems System for testing an integrated circuit of a device and its method of use
HUE026414T2 (hu) 2009-07-15 2016-05-30 Theravance Biopharma R&D Ip Llc Bifenil-vegyület kristályos szabad-bázis formája
WO2011083387A1 (en) * 2010-01-07 2011-07-14 Pfizer Limited Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
EP2593429B1 (de) 2010-07-13 2015-06-03 Theravance Biopharma R&D IP, LLC Verfahren zur herstellung einer biphenyl-2-yl-carbaminsäure
US8900635B2 (en) 2010-11-15 2014-12-02 Humanetics Corporation Nanoparticle isoflavone compositions and methods of making and using the same
US9084726B2 (en) 2013-11-26 2015-07-21 Humanetics Corporation Suspension compositions of physiologically active phenolic compounds and methods of making and using the same
CN107849047B (zh) * 2015-09-28 2021-01-15 四川海思科制药有限公司 一种联苯衍生物及其制备方法和在医药上的用途
CN112694434B (zh) * 2020-12-29 2023-06-16 浙江和泽医药科技股份有限公司 一种雷芬那辛新中间体及其活性亲电砌块和雷芬那辛的新制备方法
WO2023002502A1 (en) * 2021-07-17 2023-01-26 Msn Laboratories Private Ltd, R&D Center Novel process for the preparation of 1-(2-{4-[(4-carbamoylpiperidin-1-yl)methyl]- n-methylbenzamido}ethyl)piperidin-4-yl n-({1,1'-biphenyl}-2-yl)carbamate
WO2023104920A1 (en) 2021-12-09 2023-06-15 Medichem, S.A. Crystalline acetone solvate of revefenacin
CN114276290B (zh) * 2021-12-24 2024-05-28 浙江和泽医药科技股份有限公司 一种雷芬那辛无水晶型及其制备方法
CN117180235A (zh) * 2023-09-19 2023-12-08 山东京卫制药有限公司 一种无定型雷芬那辛吸入制剂
CN117263848A (zh) * 2023-09-19 2023-12-22 山东京卫制药有限公司 一种雷芬那辛的吸入喷雾剂
CN117263849A (zh) * 2023-09-19 2023-12-22 山东京卫制药有限公司 一种雷芬那辛三水合物晶型及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2425983C3 (de) * 1973-06-12 1978-09-14 Toyama Chemical Co. Ltd., Tokio Sulfonsäuresalze von Acylcholinen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung
WO1995021820A1 (fr) 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Nouveau derive du carbamate et composition correspondante
ATE216903T1 (de) * 1996-02-21 2002-05-15 Schering Corp Inhalator für pulverartiges medikament
US6006747A (en) * 1997-03-20 1999-12-28 Dura Pharmaceuticals, Inc. Dry powder inhaler
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
UA73543C2 (uk) * 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
US7238709B2 (en) * 1999-12-07 2007-07-03 Theravance, Inc. Therapeutic carbamates
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US20050113113A1 (en) * 2001-11-15 2005-05-26 Reed Mark J. Enhanced wireless phone
TW200526547A (en) * 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
PE20050973A1 (es) * 2003-10-29 2005-11-19 Theravance Inc Sales de acido naftalen-1,5-disulfonico de un compuesto de 4-amino-1-(piridilmetil)piperidina como antagonistas de receptores muscarinicos
TWI341836B (en) * 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
TW200540154A (en) * 2004-06-10 2005-12-16 Theravance Inc Crystalline form of a substituted pyrrolidine compound
TWI372749B (en) 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
US20060205949A1 (en) * 2005-03-10 2006-09-14 Theravance, Inc. Crystalline forms of a biphenyl compound
US8037880B2 (en) * 2006-04-07 2011-10-18 The University Of Western Ontario Dry powder inhaler
US8377956B2 (en) * 2010-03-01 2013-02-19 Xenoport, Inc. Use of (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence

Also Published As

Publication number Publication date
US20160168120A1 (en) 2016-06-16
AR106744A2 (es) 2018-02-14
US20140288033A1 (en) 2014-09-25
KR101270183B1 (ko) 2013-05-31
WO2006099165A1 (en) 2006-09-21
US8716313B2 (en) 2014-05-06
IL185471A (en) 2012-02-29
ES2337604T3 (es) 2010-04-27
PE20061347A1 (es) 2007-02-03
JP2008533036A (ja) 2008-08-21
CN101163677A (zh) 2008-04-16
TWI372749B (en) 2012-09-21
AR053336A1 (es) 2007-05-02
PT1856050E (pt) 2010-02-17
MY147792A (en) 2013-01-31
KR20070113283A (ko) 2007-11-28
US20100048622A1 (en) 2010-02-25
US20180051004A1 (en) 2018-02-22
US20070298112A1 (en) 2007-12-27
US7700777B2 (en) 2010-04-20
TW200714586A (en) 2007-04-16
US10577347B2 (en) 2020-03-03
CN101163677B (zh) 2012-01-04
DE602006010668D1 (de) 2010-01-07
BRPI0608446A2 (pt) 2009-12-29
JP5009894B2 (ja) 2012-08-22
US8921395B2 (en) 2014-12-30
US20150152054A1 (en) 2015-06-04
MX2007011083A (es) 2008-02-19
AU2006223325A1 (en) 2006-09-21
JP2012107066A (ja) 2012-06-07
DK1856050T3 (da) 2010-02-01
US20100021395A1 (en) 2010-01-28
US20130125887A1 (en) 2013-05-23
US20220388981A1 (en) 2022-12-08
PL1856050T3 (pl) 2010-05-31
US9249099B2 (en) 2016-02-02
US20100256185A1 (en) 2010-10-07
SI1856050T1 (sl) 2010-04-30
CA2599236A1 (en) 2006-09-21
EP1856050A1 (de) 2007-11-21
US9656993B2 (en) 2017-05-23
HK1114608A1 (en) 2008-11-07
EP1856050B1 (de) 2009-11-25
US11390603B2 (en) 2022-07-19
HRP20100035T1 (hr) 2010-02-28
US20200317641A1 (en) 2020-10-08
CY1109775T1 (el) 2014-09-10
IL185471A0 (en) 2008-01-06
US8377965B2 (en) 2013-02-19
US20070112027A1 (en) 2007-05-17
AU2006223325B2 (en) 2011-12-22
US8242137B2 (en) 2012-08-14
CA2599236C (en) 2013-06-25

Similar Documents

Publication Publication Date Title
ATE449762T1 (de) Kristalline formen einer biphenylverbindung
ATE520660T1 (de) Kristalline formen einer dimethylphenylverbindung
ATE479682T1 (de) Kristalline form einer chinolin-carboxamid- verbindung
LTC2004635I2 (lt) Pakeistieji enaminokarbonilo junginiai
DK1778672T3 (da) Krystallinsk form af en biphenylforbindelse
DE602005013640D1 (de) Motoreinheit einer Fahrradgangschaltung
DE602006002201D1 (de) Befestigungsanordung einer Fahrradleuchte
DK2185567T3 (da) Substituerede bicyclolactam-forbindelser
DE602006017080D1 (de) Einer verpackung
ATE443056T1 (de) Substituierte n-sulfonylaminophenylethyl-2- phenoxyacetamidverbindungen
GB0504995D0 (en) Use of a compound
DE602006020758D1 (de) Längslenker einer aufhängung
ATE509925T1 (de) Substituierte bicyclocarbonsäureamidverbindungen
DE602007012974D1 (de) Mechanismus zur Hilfe bei der Bedienung einer Kupplung
BRPI0821837A2 (pt) Processo para a preparação de 6-substituídas-1-(2h)-isoquinolinonas
BRPI0907052A2 (pt) Processo para a preparação de compostos
EP1858844A4 (de) Neue kristalline formen antidiabetischer verbindungen
DE112005003630A5 (de) Herstellung einer Welle-Naben-Verbindung
BRPI0912512A2 (pt) Processo para a preparação de compostos
BRPI0610721A2 (pt) processo para a preparação de um composto
DK2154123T3 (da) Fremgangsmåde til fremstilling af en benzaldehydforbindelse
DE102006003589B8 (de) Sumpf einer Geschirrspülmaschine
DE102005021703B8 (de) Zubringer einer Magazin-Vorrichtung
BRPI0818455A2 (pt) Processo para a preparação de 7-alil-6-hidróxi-indanos substituídos
ES1060667Y (es) Elemento conector para el mango de un cazo

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1856050

Country of ref document: EP